Overall, this single-cell sequencing study sheds light on tumor heterogeneity and identifies FABP6 as a potential driver of esophageal carcinoma progression and immunotherapy resistance, meriting further investigation as both a predictive biomarker and therapeutic target. This evidence concerns the gene FABP6 and carcinoma of esophagus.